Literature DB >> 7698567

Inherited disorders of coagulation appear to protect against inflammatory bowel disease.

N P Thompson1, A J Wakefield, R E Pounder.   

Abstract

BACKGROUND/AIMS: Crohn's disease and ulcerative colitis seem to be rarely associated with inherited diseases of coagulation. Histological and hematologic studies suggest that thrombotic mesenteric microvascular occlusion is involved in the pathogenesis of inflammatory bowel disease. The aim of this study was to perform a national survey to determine the prevalence of inflammatory bowel disease among patients with inherited disorders of coagulation.
METHODS: Using a postal and telephone questionnaire survey sent to directors of all 129 hemophilia centers in the United Kingdom, the number of patients with inflammatory bowel disease and either hemophilia or von Willebrand's disease was determined. The expected number of cases of inflammatory bowel disease in this population was estimated using published data.
RESULTS: Of 6433 patients with hemophilia and 3129 patients with von Willebrand's disease, 4 cases of Crohn's disease were reported compared with expected 11.97-16.58 cases (standardized morbidity ratio, 0.33-0.24; 95% confidence interval, 0.90-0.01; P < 0.05). Ulcerative colitis also occurred significantly less frequently than expected: 9 observed cases in comparison with expected 19.43-31.35 cases (standardized morbidity ratio, 0.46-0.29; 95% confidence interval, 0.91-0.01; P < 0.025).
CONCLUSIONS: This epidemiological study provides further evidence that thrombosis and vascular occlusion may be important in the pathogenesis of inflammatory bowel disease.

Entities:  

Mesh:

Year:  1995        PMID: 7698567     DOI: 10.1016/0016-5085(95)90197-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  32 in total

1.  Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Dilaveraki; I G Vlachonikolis; E Vardas; G Vrentzos; E Ganotakis; I A Mouzas; A Gravanis; D Emmanouel; E A Kouroumalis
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey.

Authors:  Serif Yilmaz; Kadim Bayan; Yekta Tüzün; Sabri Batun; Abdullah Altintaş
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

Review 3.  Clinical relevance of proteinase activated receptors (pars) in the gut.

Authors:  N Vergnolle
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

4.  Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 5.  Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.

Authors:  Livija Deban; Carmen Correale; Stefania Vetrano; Alberto Malesci; Silvio Danese
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

Review 6.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

7.  Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives.

Authors:  C Folwaczny; N Noehl; S P Endres; W Heldwein; K Loeschke; H Fricke
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

Review 8.  Immunopathology of human inflammatory bowel disease.

Authors:  P Brandtzaeg; G Haraldsen; J Rugtveit
Journal:  Springer Semin Immunopathol       Date:  1997

Review 9.  Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature.

Authors:  Thomas D Martin; Simon S M Chan; Andrew R Hart
Journal:  Dig Dis Sci       Date:  2014-11-19       Impact factor: 3.199

10.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.